10.06.2025 • News

IMCD to Grow Lubrizol’s Medical Solutions in North America

Lubrizol, a medical-grade thermoplastic polyurethane (TPU) solutions provider, has expanded its distribution agreement with IMCD to help meet demand for medical solutions in the US and Canada.

The collaboration aims to expand a well-established medical TPU-focused partnership in Europe to North America, with IMCD empowered to enhance market penetration, efficiently manage inventory, and strengthen customer relationships.

Lubrizol has an extensive range of medical-grade TPU solutions and differentiated design, development, and manufacturing services for medical devices. IMCD is a partner for the distribution and formulation of specialty chemicals and ingredients. The company has developed expertise in medical-grade polymers and established an extensive presence in the medical and healthcare market, combining partnerships with leading suppliers and a wide customer base.

“We are delighted to broaden our distribution with IMCD to include North America, as this enables us to continue to be the most trusted partner in the medical device industry, with service levels and the best-in-class materials our customers expect,” said Lu Zhang, Vice President for Engineered Polymers & Medical Solutions, Lubrizol.

“This new North American distribution agreement adds another layer to the strong, successful distribution partnership IMCD and Lubrizol have enjoyed for many years,” said Jean-Paul Scheepens, President of IMCD US. “We are eager to bring Lubrizol innovation to new customers.”

Company

Logo:

IMCD Group B.V.

Wilhelminaplein 32
3072 Rotterdam
Netherlands

Company contact







Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read